Janus Henderson Group
TCRT icon

Janus Henderson Group’s Alaunos Therapeutics TCRT Stock Holding History

Janus Henderson Group’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-290
Closed -$28K – 2682
2022
Q1 		$28K Hold
290
– – ﹤0.01% 2631
2021
Q4 		$48K Buy
290
+146
+101% +$32.1K ﹤0.01% 2540
2021
Q3 		$39K Buy
+144
New +$44K ﹤0.01% 2182
2013
Q3 		– Sell
-1,233
Closed -$389K – 769
2013
Q2 		$389K Buy
+1,233
New +$342K ﹤0.01% 672

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Janus Henderson Group's TCRT Position: Q2 2022 in Review

Janus Henderson Group sold out of Alaunos Therapeutics (TCRT) in Q2 2022, closing a stake of 290 shares — an estimated $28K sold.

Janus Henderson Group first reported a position in TCRT in Q2 2013 and held it in 4 quarters. The position peaked at $389K in Q2 2013. 124 funds tracked by Wall St. Rank hold TCRT as of Q2 2022.

  • Janus Henderson Group reported no remaining Alaunos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Janus Henderson Group sold 290 Alaunos Therapeutics shares in Q2 2022, an estimated $28K.
  • Janus Henderson Group first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 4 quarters.
  • Janus Henderson Group's Alaunos Therapeutics position peaked at $389K in Q2 2013.
  • 124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2022.

Based on Janus Henderson Group's 13F filing for Q2 2022, filed 15 Aug 2022.